Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPular GUILTY PILOT
2024-518464-12-00Phase 4Authorised
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of clopidogrel in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and coronary arteriosclerosis, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Composite ischemic endpoint at 6 months and Composite bleeding endpoint at 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
clopidogrel
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2024-518464-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518464-12-00.